QQQ   416.98 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.98 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.98 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.98 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
Free Trial
NASDAQ:MYOS

MYOS RENS Technology (MYOS) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free MYOS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$1.01
▼
$11.40
52-Week Range
N/A
Volume
N/A
Average Volume
1.68 million shs
Market Capitalization
$16.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media

About MYOS RENS Technology

MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.

MYOS Stock News Headlines

December 23, 2023 | bbc.com
Ren Zhengfei says US government 'underestimates' Huawei
May 11, 2023 | marketwatch.com
Bio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
May 8, 2023 | marketwatch.com
Latest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and Restraints
April 13, 2023 | marketwatch.com
Bio-active Peptides Market Size Dynamics 2023-2029
March 21, 2023 | marketwatch.com
Global Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027
March 13, 2023 | marketwatch.com
Bio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027
September 28, 2022 | marketwatch.com
Bio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
August 4, 2022 | marketwatch.com
Bio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries Data
September 26, 2021 | yahoo.com
ICYMI: Everything you need to know about the iPhone 13
July 29, 2021 | nasdaq.com
MYOS RENS Technology Inc. Common Stock (MYOS)
See More Headlines
Receive MYOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOS RENS Technology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2019
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MYOS
CUSIP
N/A
CIK
1402479
Web
www.myosrens.com
Phone
(905) 812-0023
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,260,000.00
Net Margins
-277.82%
Pretax Margin
N/A
Return on Equity
-166.68%
Return on Assets
-104.95%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
3.78
Quick Ratio
1.94

Sales & Book Value

Annual Sales
$1.03 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.13 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
12,192,000
Free Float
N/A
Market Cap
$16.70 million
Optionable
Not Optionable
Beta
1.08
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Ed Kilroy
    President, Chief Executive Officer & Director
  • Ryan Ferguson
    Chief Financial Officer, Secretary & Treasurer
  • Fraser Mackay
    Chief Information Officer
  • David John Rawlins
    Chief Commercial Officer
  • Neil Prezioso
    Chief Pharmacy Officer

Key Competitors

View All Competitors

MYOS Stock Analysis - Frequently Asked Questions

How were MYOS RENS Technology's earnings last quarter?

MYOS RENS Technology Inc. (NASDAQ:MYOS) issued its earnings results on Tuesday, August, 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.14 million. MYOS RENS Technology had a negative trailing twelve-month return on equity of 166.68% and a negative net margin of 277.82%.

What other stocks do shareholders of MYOS RENS Technology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MYOS RENS Technology investors own include Chesapeake Energy (CHKAQ), Catalyst Pharmaceuticals (CPRX), Biocept (BIOC), Global Blood Therapeutics (GBT), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX) and BioLineRx (BLRX).

This page (NASDAQ:MYOS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends